Methohexital
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Methohexital: From General Anesthesia Induction to Insomnia
One-Sentence Summary
Methohexital is an ultra-short-acting IV barbiturate anesthetic, used clinically mainly for anesthesia induction (notably electroconvulsive therapy, ECT). The TxGNN model predicts it may be effective for Insomnia, but this ranking currently has zero clinical trials and zero publications supporting it — the prediction score is high, but the evidence behind it is empty.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded — no US license found; known clinical use is IV anesthesia induction (commonly for ECT), based on evidence-pack context |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a Data Gap). Based on information present elsewhere in this evidence pack, methohexital is an ultra-short-acting barbiturate general anesthetic, used clinically as an induction agent — most notably for ECT — with an effect duration of only a few minutes.
On mechanistic grounds, barbiturates as a class enhance GABA-A receptor activity, which is the same broad mechanism used by sedative-hypnotics for insomnia, and this is likely why TxGNN scored the drug/disease pair highly. However, this analogy does not hold up pharmacokinetically: methohexital’s ultra-short duration of action and IV-only administration make it fundamentally unsuited to sustained sleep induction/maintenance, which is what insomnia treatment requires. No clinical trial or published literature searches (ClinicalTrials.gov, ICTRP, PubMed) returned any results for methohexital + insomnia.
For context, other lower-ranked TxGNN predictions for this drug (migraine disorder, headache disorder) at least have case-report/case-series-level literature — though describing methohexital/ECT as a trigger of headache, not a treatment for it. The insomnia prediction, by contrast, has no supporting evidence of any kind; it should be treated as a pharmacological-class artifact of the model rather than a validated signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN score, this prediction has no clinical trial or literature support (Evidence Level L5) and is mechanistically implausible given methohexital’s ultra-short IV pharmacokinetics, which are incompatible with insomnia treatment. The drug is also not currently marketed in the reference jurisdiction.
To proceed, the following is needed:
- TFDA/FDA label warnings and contraindications (currently a blocking data gap)
- Mechanism of action (MOA) data from DrugBank or primary literature
- Any preclinical or mechanistic studies specifically linking methohexital to sleep induction/maintenance, before this candidate can be re-scored above L5
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.